PROTEIN POLYMER TECHNOLOGIES TO PRESENT AT THE PIPEs CONFERENCE 2005

 

SAN DIEGO, October 6 -- Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI) announced today that William N. Plamondon, Chief Executive Officer of PPTI, will present a Company update at The PIPEs Conference 2005 being held at The Waldorf-Astoria in New York on October 26 and 27.
Based on the $7.75 million PIPE financing PPTI completed last April, Mr. Plamondon will focus on the Company's past and future actions to accelerate commercialization through new product development, product acquisitions and enhanced regulatory approval strategies.

 

Contacts

J. Thomas Parmeter, Ph.D. Chairman Protein Polymer Technologies, Inc. (858) 558-6064 info@ppti.com

Erin Davis Director of Communications and Investor Relations Protein Polymer Technologies, Inc. (858) 558-6064 x 120 edavis@ppti.com

About Protein Polmer Technologies

Protein Polymer Technologies, Inc., is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The company is headquartered in San Diego, California. For additional information about the company, please visit http://www.ppti.comhttp://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core technology with corresponding issued and pending patents in key international markets.

Safe Harbo

This press release contains forward-looking statements that are based on management’s views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company’s activities include raising adequate capital to continue operations scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company’s 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.